Antibacterial activity of a berberine nanoformulation
Source abstract
Abstract
This study describes the preparation of berberine (BBR) in nanoformulation to enhance its solubility and increase its antibacterial effectiveness against hospital-acquired infections. BBR nanoparticles (BBR NPs) were formed by antisolvent precipitation (ASP) using glycerol as a safe organic solvent. UV–vis absorption spectra demonstrated that the solubility of BBR NPs was greatly enhanced compared to that of pure BBR. Glycerol played a role as a stabilizer for BBR NPs through the formation of hydrogen bonds between glycerol and BBR NPs. The prepared BBR NPs have a narrow size distribution with an average diameter of 156 nm at a concentration of 2.0 mg/mL, measured by dynamic light scattering. After nanoformulation, the concentration of BBR NPs could reach up to 5.0 mg/mL, which is much higher than the saturation concentration without treatment. Results show a strongly enhanced antibacterial activity of BBR NPs compared with that of pure BBR at the same concentration. The minimum bactericidal concentration of BBR NPs against methicillin-resistant Staphylococcus aureus and Escherichia coli O157:H7 was found to be 2.0 and 5.0 mg/mL, respectively. Transmission electron microscopy showed that BBR NPs surrounded the bacterial cells and severely damaged the cell walls. Therefore, BBR NPs prepared by ASP appear to be a potential candidate for the treatment of bacterial pathogens.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Berberine and alkaloids research · Antibiotic Resistance in Bacteria · Alkaloids: synthesis and pharmacology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. 10.14715/cmb/2018.64.8.510.14715/cmb/2018.64.8.5 ↗
2. 10.1002/ptr.239910.1002/ptr.2399 ↗
3. 10.1016/j.micpath.2020.10454210.1016/j.micpath.2020.104542 ↗
4. 10.1186/s12906-019-2558-910.1186/s12906-019-2558-9 ↗
5. 10.1186/s40249-021-00812-910.1186/s40249-021-00812-9 ↗
6. 10.1186/s13568-020-01088-210.1186/s13568-020-01088-2 ↗
7. 10.1016/j.canlet.2003.09.00210.1016/j.canlet.2003.09.002 ↗
8. 10.1186/0717-6287-47-810.1186/0717-6287-47-8 ↗
9. 10.1155/2016/875343610.1155/2016/8753436 ↗
10. 10.1016/j.bmcl.2019.12670910.1016/j.bmcl.2019.126709 ↗
11. 10.3389/fmolb.2020.62449410.3389/fmolb.2020.624494 ↗
12. 10.3389/fmicb.2019.0258410.3389/fmicb.2019.02584 ↗
13. 10.1016/j.actbio.2010.08.02810.1016/j.actbio.2010.08.028 ↗
14. 10.1089/jmf.2005.8.45410.1089/jmf.2005.8.454 ↗
15. Peng · International Journal of Clinical and Experimental Pathology · 2015 · 8 · 5217
16. 10.1038/srep2474810.1038/srep24748 ↗
17. 10.1016/j.bmcl.2006.12.08510.1016/j.bmcl.2006.12.085 ↗
18. 10.1186/s12985-016-0674-410.1186/s12985-016-0674-4 ↗
19. 10.1002/ptr.619610.1002/ptr.6196 ↗
20. 10.1007/s00705-020-04706-310.1007/s00705-020-04706-3 ↗
21. 10.3390/v1302028210.3390/v13020282 ↗
22. 10.1016/j.phyplu.2022.10025210.1016/j.phyplu.2022.100252 ↗
23. 10.3390/v1312243710.3390/v13122437 ↗
24. 10.1080/07391102.2020.172456810.1080/07391102.2020.1724568 ↗
25. 10.1016/j.sjbs.2020.10.00610.1016/j.sjbs.2020.10.006 ↗
26. 10.2147/dddt.s15612310.2147/dddt.s156123 ↗
27. 10.1016/j.jconrel.2008.03.00210.1016/j.jconrel.2008.03.002 ↗
28. 10.1016/j.ijpharm.2009.09.03010.1016/j.ijpharm.2009.09.030 ↗
29. 10.1080/10717544.2017.132106210.1080/10717544.2017.1321062 ↗
30. 10.1016/j.ijpharm.2017.04.07310.1016/j.ijpharm.2017.04.073 ↗
31. 10.1016/j.biopha.2018.05.06710.1016/j.biopha.2018.05.067 ↗
32. 10.1002/cplu.20200049610.1002/cplu.202000496 ↗
33. 10.1021/acsomega.0c0159210.1021/acsomega.0c01592 ↗
34. 10.1517/17425247.2014.91356810.1517/17425247.2014.913568 ↗
35. 10.1107/s205322961901543210.1107/s2053229619015432 ↗
36. 10.1016/j.saa.2017.05.07010.1016/j.saa.2017.05.070 ↗
37. 10.1208/s12249-010-9520-y10.1208/s12249-010-9520-y ↗
38. 10.1021/acs.jchemed.5b0101410.1021/acs.jchemed.5b01014 ↗
39. 10.7763/ijcea.2013.v4.32110.7763/ijcea.2013.v4.321 ↗
40. 10.1007/bf0150820910.1007/bf01508209 ↗
41. 10.1099/jmm.0.00010610.1099/jmm.0.000106 ↗
42. 10.1016/j.micpath.2016.11.01110.1016/j.micpath.2016.11.011 ↗
43. 10.3389/fmicb.2020.0062110.3389/fmicb.2020.00621 ↗
44. 10.1039/d0ra07573f10.1039/d0ra07573f ↗
45. 10.1007/s11664-017-5315-110.1007/s11664-017-5315-1 ↗